Home

search

current Issue

archive

Site help

 
 
Click here to subscribe

 

GGH at a glance

Editorial Board

Contact Us

Subscribe

Online Resources

PDF Reader

Announcements

GH Guidelines

Volume 19, Issue 1, March 2003
Table of Contents 19-1
Kyphosis in Turner Syndrome
 
PediaLink.org (Vol. 109) 6/2002. PPE 93.
 

Abstract

Elder and colleagues performed lateral thoracic spine and standing anterior-posterior scoliosis radiographs in 25 of 30 girls between the ages of 5 and 18 years with Turner Syndrome. Excessive kyphosis was defined as an A-P curvature greater than 40%, vertebral wedging as an A-P deformity greater than 5% at any vertebral body, and scoliosis as a lateral curve greater than 10%. Karyotype, age, height, weight, and body mass index percentile, and use and duration of growth hormone, oxandrolone (anavar), and/or estrogen were recorded and entered into a linear regression analysis to determine significant predictors of kyphosis or kyphosis and wedging.  Of the 25 subjects studied, 15 (60%) had abnormal radiographic findings. Ten (40%) had excessive kyphosis, 10 (40%) had vertebral wedging, and 5 (20%) had scoliosis.  All girls older than 14 years of age (N=8) had excessive kyphosis and wedging. 

The subjects were 12.0 +3.6 years old.  Sixty percent had a 45X karyotype, 80% had received GH therapy, and 36% had received estrogen therapy. Logistic regression analysis revealed that chronologic age alone was predictive of excessive kyphosis/wedging, (P=0.053). Stepwise linear regression analysis also showed that chronologic age was predictive of the degree of kyphosis (P=0.032).  None of the other variables were predictive.  The authors remarked upon the high prevalence of vertebral wedging and excessive kyphosis in their study population.   They noted that this is markedly increased compared with the reported prevalence of 3% in the general population.  The cause of the scoliosis is apparently multi-factorial, but may include mechanical factors, osteoporosis, adolescent growth spurt, and intrinsic bone defect. Girls with Turner syndrome are known to have a significant number of bony abnormalities, including hypoplasia of cervical vertebrae, and hemivertebrae, although these were not found in the study population. The authors also note that their inability to determine the contribution of age and hormonal therapies to the development of kyphosis may be the result of the small number of subjects studied.

PediaLink.org (Vol. 109) 6/2002. PPE 93.

Editor’s Comment: With such a huge number of Turner subjects (40%) with reported excessive kyphosis, it is surprising that there are not more reports of its prevalence. Indeed this study suggests all girls with Turner syndrome should have routine radiographic screening and should be evaluated by an orthopedist. It is also surprising that more information is not available regarding the probable pathogenesis of these deformities. Since the vast majority of subjects in the study had received or were receiving GH, its contribution to the development of the kyphosis is impossible to determine. However, information from subjects in larger multi-centered databases of individuals who have and have not been treated with GH, would be important to access in order to determine its possible role in the genesis of this deformity.  Some information regarding the prevalence of kyphosis in children treated with GH who either had or did not have GH deficiency also could be an important comparison group. Unfortunately this study raises many more questions than it answers, but will probably stimulate other centers to evaluate girls with Turner syndrome.  Perhaps a multi-centered survey could help provide a better understanding of this problem.  The Growth, Genetics and Hormones Editorial Board welcomes a letter to the editor from readers who have knowledge of data pertinent to the questions raised.

William L. Clarke, MD

Print version (pdf) |Printer-Friendly


Home | Search | Current Issue | Archive | Site Help

GGH at a Glance | Editorial Board | Contact Us | Subscribe | Announcements

Online Resources | PDF Reader | Genentech, Inc. | Prime Health Consultants, Inc.

Copyright ©2003 Prime Health Consultants, Inc.